These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32410794)

  • 41. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.
    Arun B; Bayraktar S; Liu DD; Gutierrez Barrera AM; Atchley D; Pusztai L; Litton JK; Valero V; Meric-Bernstam F; Hortobagyi GN; Albarracin C
    J Clin Oncol; 2011 Oct; 29(28):3739-46. PubMed ID: 21900106
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
    Golan T; Sella T; O'Reilly EM; Katz MH; Epelbaum R; Kelsen DP; Borgida A; Maynard H; Kindler H; Friedmen E; Javle M; Gallinger S
    Br J Cancer; 2017 Mar; 116(6):697-702. PubMed ID: 28183138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
    Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
    Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
    Ruiz de Sabando A; Urrutia Lafuente E; García-Amigot F; Alonso Sánchez A; Morales Garofalo L; Moreno S; Ardanaz E; Ramos-Arroyo MA
    BMC Cancer; 2019 Nov; 19(1):1145. PubMed ID: 31771539
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.
    Mitamura T; Sekine M; Arai M; Shibata Y; Kato M; Yokoyama S; Yamashita H; Watari H; Yabe I; Nomura H; Enomoto T; Nakamura S;
    Jpn J Clin Oncol; 2020 Dec; 50(12):1380-1385. PubMed ID: 32676635
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer.
    Carleton N; Zou J; Fang Y; Koscumb SE; Shah OS; Chen F; Beriwal S; Diego EJ; Brufsky AM; Oesterreich S; Shapiro SD; Ferris R; Emens LA; Tseng G; Marroquin OC; Lee AV; McAuliffe PF
    JAMA Netw Open; 2021 Apr; 4(4):e216322. PubMed ID: 33856473
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy.
    Toss A; Molinaro E; Venturelli M; Domati F; Marcheselli L; Piana S; Barbieri E; Grandi G; Piombino C; Marchi I; Tenedini E; Tagliafico E; Tazzioli G; Cortesi L
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429297
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Clinical, Pathological, and Prognostic Features in
    Doğan İ; Aydın E; Yazıcı H; Saip P
    Eur J Breast Health; 2022 Oct; 18(4):323-328. PubMed ID: 36248747
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Analysis of prognosis and influencing factors of No. 253 lymph node metastasis in descending colon, sigmoid colon, and rectal cancer: a multicenter study].
    Zhao FQ; Zhou L; Du XH; Wu AW; Yang H; Xu L; Liu XZ; Hu SD; Xiao Y; Liu Q
    Zhonghua Wai Ke Za Zhi; 2023 Sep; 61(9):760-767. PubMed ID: 37491168
    [No Abstract]   [Full Text] [Related]  

  • 50. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
    Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Long-term recurrence rate and survival in different aged patients with breast cancer undergoing breast conserving therapy].
    Wang LZ; Li JF; Wang TF; Xie YT; Fan ZQ; He YJ; Ouyang T
    Zhonghua Wai Ke Za Zhi; 2021 Feb; 59(2):127-133. PubMed ID: 33378805
    [No Abstract]   [Full Text] [Related]  

  • 53. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
    Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
    JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prognostic value and initial exploratory research on TNM staging method of tumor deposits in stage III colon cancer].
    Qin Q; Yang L; Zhou AP; Wang JW; Zhong DS
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Dec; 22(12):1152-1158. PubMed ID: 31874531
    [No Abstract]   [Full Text] [Related]  

  • 55. Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer.
    Feng L; Jin F
    Oncol Lett; 2019 Apr; 17(4):3687-3700. PubMed ID: 30881493
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Application of 21-gene recurrence risk score in patients with breast cancer].
    Chen Q; Shen HX; Wang YL; Zhao J; Ma JF; Wang SQ; Fu PF
    Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):678-684. PubMed ID: 38955698
    [No Abstract]   [Full Text] [Related]  

  • 57. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
    Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M
    Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Analysis of risk factors of axillary lymph node metastasis and prognosis in T1 breast cancer: a large-scale retrospective study based on the SEER database].
    Wang WY; Meng XZ; Li N; Zeng HM; Liu JX; Feng KX; Wang PL; Wang X
    Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(27):2152-2158. PubMed ID: 34275251
    [No Abstract]   [Full Text] [Related]  

  • 59. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
    Sharma P; Klemp JR; Kimler BF; Mahnken JD; Geier LJ; Khan QJ; Elia M; Connor CS; McGinness MK; Mammen JM; Wagner JL; Ward C; Ranallo L; Knight CJ; Stecklein SR; Jensen RA; Fabian CJ; Godwin AK
    Breast Cancer Res Treat; 2014 Jun; 145(3):707-14. PubMed ID: 24807107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer.
    You C; Xiao Q; Zhu X; Sun Y; Di G; Liu G; Hou Y; Chen C; Wu J; Shao Z; Gu Y; Hu Z
    Gland Surg; 2021 Jan; 10(1):262-272. PubMed ID: 33633982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.